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This is Part I of what will be a 2-part
monograph, and consists of 5 largely un-
related papers on trial methodology. Two
of these are of particular interest, because
they take a sample ofreal trials in an attempt
to characterize how trials are actually done
in practice.
Bardelli and Saracci show that, whilst
half of the chemotherapy and radiotherapy
trials they studied were randomized, very
few of the immunotherapy trials were. They
also show that most cancer trials do not
attempt to monitor the quality of life in any
useful way. I cannot whollyshare their dismay
at this, however, because having to answer
several questions relating to quality of life
at each follow-up in a clinical trial may
generate an alarmingly large amount of
data which serves only to demonstrate the
obvious. However, it would certainly be
preferable if the percentages of patients
suffering alopecia, vomiting, ulceration,
serious infection and even death in response
to chemo- or radio-therapy were more
commonly reported.
Pocock, Armitage and Galton have studied
a random sample of the cancer trials listed
by the UICC, and find that most of the
trials they studied were not even trying to
enter large numbers of patients, over 80 00
of trials aiming to enter under 200 patients.
This means that even if a moderate but
medically important difference really does
exist between the treatments being compared
in a typical clinical trial, random differences
between the two small treatment groups
are likely to mask the demonstration of this
difference; whereas conversely, quite large
apparent differences may appear just by
chance, especially in trials with fewer than
100 patients.
Gehan describes a particular mathematical
method (Cox's method) for adjusting for
prognostic features when analysing clinical
trials. Cox's method is valid and is in some
important ways optimal for this purpose,
but it has the disadvantage that non-statisti-
cians cannot follow it, neither in detail nor
even in principle, and so, where possible,
simple retrospective stratification may be
preferable, as the underlying principles are
easier to explain to non-statisticians. Gehan,
as an example of Cox's method, tries to
correct for some systematic differences be-
tween a group of actively treated breast-
cancer patients and a group of historical
controls. This might, however, be a mis-
leading example, not only because these
groups might also have differed in various
respects which were not measured, but also
because any purely random errors in the
measurement of prognostic information can
be shown to result in incomplete adjustment
for any systematic biases that might exist.
Magnus and Miller discuss methodological
considerations that might govern any future
prophylactic cancer trials that are under-
taken. It is difficult to imagine a more
thorough article being written on this
subject, but it is difficult to evaluate a
discussion of the difficulties inherent in a
class of studies which as yet hardly exists.
Finally, there is a chapter by Higgins on
legal and ethical problems, which is probably
unique among publications on these questions
in being almost too brief.
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Tumours-Basic Principles and Clinical
Aspects C. J. Louis (1978) Edinburgh:
Churchill Livingstone. 334 pp. £4.95.
This small paperback volume attempts to
encompass the aetiology, pathology and
treatment of malignant disease. In 300 small
pages this is clearly a difficult undertaking,
and perhaps the author has not been
altogether equal to the task. The first section
on the biology of cancer is really very
disappointing. The author uses very little
recent information of great importance for
trainee physicians. In particular, none of
the newer biology of invasion and meta-
stasis is referred to at all. Similarly the
same has to be said for the chapters on the
biology of the cancer cell, chemical carcino-